European News

The report on Molecure’s financial results can be accessed via its website, however Marcin Szumowski, CEO and president of the management board of Molecure, said: “We are delighted with the progress we are making on our strategic objectives, accomplished year to date. Our confidence in OATD-01’s potential to be a best and first-in-class disease modifying therapy for sarcoidosis has been enhanced over the period as a result of our discussions with a group of leading global experts and clinicians in sarcoidosis. Their input has also been important to ensure the successful planning and execution of this high priority clinical programme. We are equally excited about the opportunity for OATD-02 in cancer, given this novel molecule’s clearly differentiated mode of action, and remain on track to start a phase 1 study in late 2022.”

Its planned R&D day in December 2022 is intended to provide updates on the development of Molecure’s projects, with a focus on OATD-01 for the treatment of sarcoidosis and OATD-02 to treat cancer.

Molecure is currently preparing for its multicentre phase 2 trial for OATD-01, and hope that it will soon be able to initiate a phase 1 clinical trial for OATD-02. It is also aiming to continue to develop its mRNA platform, including collaborations with leading RNA centres.